Printer Friendly

SYSTEMIX ENTERS STRATEGIC R&D COLLABORATION WITH SANDOZ; COMPANIES TO RESEARCH AND DEVELOP USES FOR HUMAN STEM CELL GROWTH FACTORS

 SYSTEMIX ENTERS STRATEGIC R&D COLLABORATION WITH SANDOZ; COMPANIES
 TO RESEARCH AND DEVELOP USES FOR HUMAN STEM CELL GROWTH FACTORS
 PALO ALTO, Calif., June 19 /PRNewswire/ -- SyStemix, Inc. (NASDAQ: STMX), today announced it has signed a binding agreement with Sandoz Pharma Ltd., a unit of Sandoz Ltd., to work jointly to identify and isolate a gene which encodes a growth factor that is responsible for human stem cell self-renewal.
 SyStemix currently holds a U.S. patent for the separation of human stem cells from bone marrow and for their cellular composition. Under terms of the agreement, SyStemix will grant Sandoz worldwide rights to stem cell growth factors (SCGF) for in vivo uses. SyStemix will retain worldwide rights to use the growth factors ex vivo and the option to co- promote the product in the United States for in vivo uses. Terms of the agreement have not been released.
 "This agreement solidifies the collaborative nature of the SyStemix- Sandoz relationship, and we are happy to have a concrete project up and running so soon," said Linda Sonntag, president and CEO of SyStemix. "It also expands SyStemix' reach into the global marketplace by partnering with one of the top pharmaceutical companies in the world."
 Sandoz Pharma Ltd. Chairman Max Link said, "This is the first of, we hope, many collaborations we will establish with our new partner and complements our already extensive R&D portfolio of hematopoietic growth factors, which includes granulocyte-macrophoge colony stimulating factor (GM-CSF), Interleukin 3 (IL-3), Interleukin 6 (IL-6) and Leukemia Inhibitory Factor (LIF)."
 SCGFs are proteins believed to cause hematopoietic stem cells to regenerate. This action ensures that the body's capacity to provide a constant supply of new blood and immune cells is maintained. Stem cells are the only cell believed to have such a capability, but comprise less than one-half of 1 percent of bone marrow cells. However, their number could be augmented by application of SCGF. The potential applications of the SCGF would initially be in chemotherapy, radiation treatment and bone marrow transplantation. It also promises to be useful in the treatment of immunosuppressive diseases.
 SyStemix, Inc., based in Palo Alto, is primarily engaged in the development of cellular processes and products based on human hematopoietic stem cells, human megakaryocytes and megakaryocyte progenitors. Sandoz Pharma Ltd. is a leading research-based pharmaceutical company with headquarters in Basle, Switzerland. Its products are used in the prevention of organ rejection after transplantation and in endocrinological, immunological, cardiovascular and central nervous system diseases. Sandoz Ltd., the parent company of Sandoz Pharma Ltd., holds 60 percent of SyStemix common stock.
 -0- 6/19/92
 /CONTACT: Linda Sonntag, president & CEO, of SyStemix, 415-856-4901, ext. 218; or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for SyStemix/
 (STMX SDOZY) CO: SyStemix, Inc.; Sandoz Ltd. ST: California IN: MTC SU:


GK-OS -- NY009 -- 1830 06/19/92 10:10 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 19, 1992
Words:475
Previous Article:ALL AMERICAN SEMICONDUCTOR ANNOUNCES EFFECTIVENESS OF REGISTRATION STATEMENT
Next Article:SUN DISTRIBUTORS L.P. ANNOUNCES CASH DISTRIBUTIONS
Topics:


Related Articles
SYSTEMIX REPORTS SECOND QUARTER AND SIX MONTH RESULTS
SYSTEMIX MOVES TO STATE-OF-THE-ART FACILITY
SYSTEMIX REPORTS THIRD QUARTER AND NINE MONTH RESULTS
SYSTEMIX APPOINTS NATIONAL CANCER INSTITUTE SENIOR INVESTIGATOR AS DIRECTOR OF GENE THERAPY
SYSTEMIX REPORTS 1992 RESULTS
SYSTEMIX SIGNS COLLABORATIVE AGREEMENT WITH CENTRE LEON BERARD
SYSTEMIX REPORTS THIRD QUARTER AND NINE MONTH RESULTS
SYSTEMIX REPORTS SECOND QUARTER AND SIX MONTH RESULTS
SYSTEMIX' DISEASE-FREE STEM CELL TRANSPLANTS MAY CONTRIBUTE TO IMMUNE SYSTEM RECOVERY
SYSTEMIX REPORTS FOURTH QUARTER AND TWELVE MONTH RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters